



Final Appraisal Recommendation

Advice No: 3414 – November 2014

Rituximab (MabThera®) 1,400 mg solution for subcutaneous injection

Submission by Roche Products Limited

Recommendation of AWMSG

Rituximab (MabThera®) solution for subcutaneous injection is recommended as an option for use within NHS Wales for the treatment of adults for non-Hodgkin's lymphoma (NHL): for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy; as maintenance therapy for the treatment of follicular lymphoma patients responding to induction therapy; and for the treatment of patients with CD20-positive diffuse large B cell NHL in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1048), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	Roche Products Limited
Date of first issue	November 2014
Last reviewed	January 2018

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 3414:
Rituximab (MabThera®) 1,400 mg solution for subcutaneous injection. November 2014.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.